As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek, Dr. Elias Jabbour, Dr. Brady Stein and patient advocate, Andi Malitz, gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts reviewed promising results of recent studies, including telomerase inhibitors, antifibrotic treatments, the long-term benefit of the JAK inhibitor, ruxolitinib, as well as news about the promise of early intervention. Also discussed were observational studies and how these studies are providing experts with better understanding of the disease. The experts stressed the importance of balancing treatment…
Author: admin
As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek, Dr. Elias Jabbour, Dr. Brady Stein and patient advocate, Andi Malitz, gathered to discuss the latest news and research in myeloproliferative neoplasms (MPNs). The experts reviewed promising results of recent studies, including telomerase inhibitors, antifibrotic treatments, the long-term benefit of the JAK inhibitor, ruxolitinib, as well as news about the promise of early intervention. Also discussed were observational studies and how these studies are providing experts with better understanding of the disease. The experts stressed the importance of balancing treatment…
Expert Dr. Russell Szmulewitz of the University of Chicago Medical Center describes the endocrinology of prostate cancer and provides an overview of hormonal therapies. Dr. Szmulewitz examines the changing treatment paradigm including risks and benefits. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Evan Yu, MD of Seattle Cancer Care Alliance goes over next steps after FDA approval for Atezelozimab
Even though there is a tremendous access to new drug therapies, doctors have yet to determine the best way to use these new therapies. The doctors conclude that some of the most exciting therapies are monoclonal antibodies, vaccines, small molecules, cellular therapies, CAR- T cell therapy, and more. IMWG Myeloma Experts debate the latest trends in treatment June 9, 2016 Copenhagen, Denmark
Discussed are the new IMWG Criteria in MRD testing in multiple myeloma, which is to be published in Lancet Oncology. Attention is given as to how to use the testing going forward with patient care. IMWG Myeloma Experts debate the latest trends in treatment June 9, 2016 Copenhagen, Denmark
Heather Wakelee, MD of Stanford Medicine discusses genetic heterogeneity and genomic alterations in KRAS mutated NSCLC
The doctors consider mSMART classification to look at high-, intermediate-, and standard-risk myeloma. They discuss, with the increasing depth of response in myeloma with the newer drugs, how doctors should evaluate the use of these drugs with the higher-risk disease groups. IMWG Myeloma Experts debate the latest trends in treatment June 9, 2016 Copenhagen, Denmark
The third question of the series is Are you proactive regarding your patients possible comorbidities? In particular, the doctors consider patient characteristics such as age, performance status, and other health problems. They talk about when to consider stem cell transplant with frailer patients. IMWG Myeloma Experts debate the latest trends in treatment June 9, 2016 Copenhagen, Denmark
The first question of the series is What is the impact of the new diagnostic criteria? The criteria to which the doctors are referring is the SLiM CRAB criteria, which expands the former CRAB criteria. IMWG Myeloma Experts debate the latest trends in treatment June 9, 2016 Copenhagen, Denmark
Alexander Spira, MD of Virginia Cancer Specialists discusses PD-L1 expression in tumor and immune cells in the microenvironment from the POPLAR trial
Nathan Pennell, MD of Cleveland Clinic talks about the future of genotypical NSCLC immunotherapy
Dr. Omid Hamid, MD of The Angeles Clinic outlines the evidence that uveal melanoma is responsive to immunotherapy
Dr Arjun V. Balar, MD of NYU Langone Medical Center discusses how upper tract disease did better in IMVigor210 trial
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the development of evidence-based gene expression profiling to better classify breast cancer subtypes for optimising therapeutic decisions in patients with breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO) meeting in Chicago. The group explains updates related to biomarkers, chemotherapy and hormonal approaches. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Is there hope for lung cancer patients with genetic alterations who have become resistant to therapies? On location at ASCO 2016, lung cancer expert Dr. Liza Villaruz announces new information that includes advances in the field of lung cancer focused on overcoming resistance to novel inhibitors. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there any difference between external and internal factors that lead to gene mutations in lung cancer? Live from the 2016 American Society of Clinical Oncology (ASCO) meeting in Chicago, Drs. Liza Villaruz and Charu Aggarwal sat down with host, John Ratzenberger, for an Ask the Lung Cancer Expert discussion that covered questions submitted by lung cancer patients and their families. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow…
Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there any difference between external and internal factors that lead to gene mutations in lung cancer? Live from the 2016 American Society of Clinical Oncology (ASCO) meeting in Chicago, Drs. Liza Villaruz and Charu Aggarwal sat down with host, John Ratzenberger, for an Ask the Lung Cancer Expert discussion that covered questions submitted by lung cancer patients and their families. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow…
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO) meeting in Chicago. The group explains updates related to biomarkers, chemotherapy and hormonal approaches. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
What is the latest news on lung cancer immunotherapies? On location at ASCO 2016, lung cancer expert Dr. Charu Aggarwal of the University of Pennsylvania Hospital gives an update. Dr. Aggarwal gives a brief glimpse at the results of combination immunotherapy data, including crizotinib (Xalkori) and alectinib (Alecensa). Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Laura Chow discusses new combination therapies and molecularly targeted therapies, specifically in head and neck cancers.
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the development of evidence-based gene expression profiling to better classify breast cancer subtypes for optimising therapeutic decisions for patients with breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Robert Dreicer, MD at University of Virginia Health System talks about how the Atezolizumab FDA approval will spur more studies in the future
Heather Wakelee, MD at The Stanford University Medical Center outlines the therapeutic options currently available for RET altered NSCLC from ASCO 2016
Alexander Spira, MD of Virginia Cancer Specialists goes over the future of Next-Gen sequencing and who will respond and who will not to therapy
Nathan Pennell, MD at Cleveland Clinic discusses how to chose the most effective second line PD-1 or PD-L1 therapy in lung cancer
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the development of evidence-based gene expression profiling to better classify breast cancer subtypes for optimising therapeutic decisions for patients with breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Omid Hamid, MD at The Angeles Clinic Combi-d and BRIM7 trials and the extended follow-up results
Arjun Balar, MD of NYU Langone gives an overview of IMvigor 210 cohort one data and results
Justin Stebbing, MD, MA, FRCP, FRCPath, PhD from Imperial College Healthcare NHS Trust, London, UK discusses developments in anti-PD-1 and anti-PD-L1 drugs presented at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Prof Stebbing discusses a study on nivolumab and ipilimumab in 220 patients with small cell lung cancer and how these drugs might change the outlook for this disease. He further discusses the presentation on the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors and what this might mean for the future use of chemotherapy.
Dr. Evan Yu, MD of University of Washington School of Medicine notes that smoking does not predispose higher response rate to Atezolizumab according to the IMvigor210 data. ASCO 2016
Dr. Heather Wakelee, MD of The Stanford University Medical Center Wakelee_MET in NSCLC including its over expression increased copy number and MET exon 14 alterations
Bruce Johnson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the challenges associated with developing effective treatments for patients with solid tumors. Prof Johnson discusses the efforts that are being made in terms of defining subgroups of patients and relevant therapy approaches for common tumors such as breast cancer, lung cancer and colon cancer. He also talks about how for unusual tumors, the challenge is to identify therapy targets and recruit sufficient numbers of patients for trials. Recorded at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the cost of drugs in multiple myeloma (MM) and the debate around the issue. According to Prof Fonesca, the costs associated with drug development have to be accounted for and a more data-driven and free market approach are needed to solve the issue of drug affordability. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses highlights in multiple myeloma (MM) at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Prof Fonesca mentions presentations looking at the role of stem cell transplant vs conventional therapy, a meta-analysis on the use of maintenance with lenalidomide and a presentation on a dynamic approach to monitoring patients with smouldering myeloma.
Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the place of nivolumab and pembrolizumab in the current treatment landscape for relapsed Hodgkin lymphoma. According to Prof Younes, the approval by the FDA is very specific and requires that patients have had a failed autologous stem cell transplant and brentuximab vedotin. He further discusses how the new combinations may change the treatment landscape. Recorded at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical Oncology (ASCO), discusses the increasing cost of drugs and how he plans to address the issue as the president of ASCO. He mentions one of the abstracts presented at the ASCO 2016 Annual Meeting, in Chicago, IL, which showed that the cost of drugs can vary more than 5-fold from one country to another. Prof Johnson further discusses new developments, in particular biosimilars.
Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of the Phase II AIM study of ibrutinib and venetoclax (ABT-199) in relapsed/refractory mantle cell lymphoma (NCT02471391) presented at the American Society of Oncology (ASCO) 2016 Annual Meeting in Chicago, IL. Dr Tam outlines how of the eight patients who have completed a four month course, five are in complete remission (CR), two patients in partial remission, and one patient did not respond. Dr Tam further discusses the promise of this drug combination and the associated toxicities.
Alexander Spira, MD of Virginia Cancer Specialists discusses mutation load and gene profiles appear to have a significant impact on response rates and survival
Dr. Robert Dreicer, MD of the University of Virginia Health System gives an overview of PD-L1 expression on cancer cells and how they impact the endpoints and ability to respond in the IMvigor210 study
Arjun Balar, MD of New York University Langone comments on deficient mismatch repair within urothelial cancer
Dr. Evan Yu, MD of the University of Washington School of Medicine outlines the IMvigor210 trial design and patient populaiton
Dr. Heather Wakelee, MD at The Stanford University Medical Center remarks on the E1505 trial results from ASCO 2016
Alexander Spira, MD of Virginia Cancer Specialist remarks on the many different combinations of immunotherapy drugs that are being being tested due to the low toxicity of these drugs
Omid Hamid, MD Director of the Melanoma Center at The Angeles Clinic goes over the advantages and disadvantages with Binimetinib combined with Encorafenib
Dr Robert Dreicer, MD of University of Virginia Health System highlights the importance of the FDA approval of Atezolizumab at ASCO 2016
Dr. Arjun Balar, MD of NYU Langone Medical Center discusses Bevacizumab in combination with chemotherapy in metastatic urothelial cancer at ASCO 2016
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses his highlights for chronic lymphocytic leukemia (CLL) from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Dr Wierda mentions the update on venetoclax in patients who have relapsed or are intolerant to ibrutinib or idelalisib, the idelalisib plus ofatumumab as well as the bendamustine plus rituximab and idelalisib randomized trials.
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical Oncology (ASCO), discusses one of his goals of bringing precision medicine from the academic centers to community practices. As part of this, physicians will need to be provided with the right tools that will allow them to transform the care patients receive around the world. Recorded at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, in Chicago, IL.